First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

被引：0

作者：

Mark, M. ^{[1
]}

Froesch, P. ^{[2
]}

Gysel, K. ^{[3
]}

Rothschild, S. ^{[4
]}

Addeo, A. ^{[5
]}

Ackermann, C. ^{[6
]}

Chiquet, S. ^{[3
]}

Schneider, M. ^{[3
]}

Ribi, K. ^{[3
]}

Fischer, A. ^{[1
]}

Bastian, S. ^{[1
]}

von Moos, R. ^{[7
]}

Joerger, M. ^{[8
]}

Frueh, M. ^{[8
]}

机构：

[1] Cantonal Hosp Graubunden, Oncol Hematol, Chur, Switzerland

[2] Cantonal Hosp Bellinzona, Oncol, Bellinzona, Switzerland

[3] SAKK, Coordinating Ctr, Bern, Switzerland

[4] Cantonal Hosp Baden, Oncol Hematol, Baden, Switzerland

[5] Geneva Univ Hosp, Oncol, Geneva, Switzerland

[6] Hosp Thun, Oncol Hematol, Thun, Switzerland

[7] Cantonal Hosp Graubunden, Tumor & Res Ctr, Chur, Switzerland

[8] Cantonal Hosp St Gallen, Oncol Hematol, St Gallen, Switzerland

来源：

SWISS MEDICAL WEEKLY | 2023年 / 153卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

218

引用

页码：7S / 7S

页数：1

共 50 条

[1] First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Mark, Michael Thomas
Froesch, Patrizia
Gysel, Katrin
Rothschild, Sacha
Addeo, Alfredo
Ackermann, Christoph J.
Chiquet, Sabrina
Schneider, Martina
Ribi, Karin
Maranta, Angela Fischer
Bastian, Sara
Von Moos, Roger Anton Fredy
Joerger, Markus
Fruh, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Mark, Michael
Froesch, Patrizia
Gysel, Katrin
Rothschild, Sacha I.
Addeo, Alfredo
Ackermann, Christoph J.
Chiquet, Sabrina
Schneider, Martina
Ribi, Karin
Maranta, Angela Fischer
Bastian, Sara
von Moos, Roger
Joerger, Markus
Frueh, Martin
EUROPEAN JOURNAL OF CANCER, 2024, 200
[3] SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Mark, Michael
Froesch, Patrizia
Eboulet, Eric Innocents
Addeo, Alfredo
Pless, Miklos
Rothschild, Sacha I.
Janthur, Wolf-Dieter
Burmeister, Henning
Friedlaender, Alex
Schneider, Martina
Metaxas, Yannis
Joerger, Markus
Wannesson, Luciano
Schwitter, Michael
Baudoux, Nathalie
Weindler, Susanne
Biaggi-Rudolf, Christine
Fruh, Martin
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (05) : 1255 - 1262
[4] SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
Michael Mark
Patrizia Froesch
Eric Innocents Eboulet
Alfredo Addeo
Miklos Pless
Sacha I. Rothschild
Wolf-Dieter Janthur
Henning Burmeister
Alex Friedlaender
Martina Schneider
Yannis Metaxas
Markus Joerger
Luciano Wannesson
Michael Schwitter
Nathalie Baudoux
Susanne Weindler
Christine Biaggi-Rudolf
Martin Früh
Cancer Immunology, Immunotherapy, 2021, 70 : 1255 - 1262
[5] SAKK 19/17-safety analysis of first-lLine durvalumab in patients with PD-L1 positive, advanced NSCLC and a performance status of 2
Mark, M.
SWISS MEDICAL WEEKLY, 2020, : 28S - 28S
[6] Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 positive expression: A multicenter, single-arm phase 2 study
Cheng, Ying
Shen, Lin
Chen, Zhendong
Ye, Feng
Yu, Xianjun
Zhang, Xing
Ji, Dongmei
Liu, Baorui
Song, Lijie
Wu, Chunjiao
Lu, Ming
Chen, Wei
Wu, Jingxun
Gao, Heli
Weng, Desheng
Shen, Weina
Li, Rutian
Yang, Minjie
Zhou, Jinghong
Shi, Haiyan
Tan, Panfeng
Fan, Songhua
Shi, Michael
Su, Weiguo
CANCER RESEARCH, 2023, 83 (08)
[7] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) - A multicenter single-arm phase II trial
Rothschild, S. I.
Zippelius, A.
Eboulet, E. I.
Prince, S. Savic
Betticher, D.
Bettini, A.
Fruh, M.
Joerger, M.
Britschgi, C.
Peters, S.
Mark, M. T.
Ochsenbein, A. F.
Janthur, W-D.
Waibel, C.
Mach, N.
Gonzalez, M.
Froesch, P. R.
Godar, G.
Rusterholz, C.
Pless, M.
ANNALS OF ONCOLOGY, 2020, 31 : S803 - S804
[8] Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Lu, S.
Fang, J.
Liu, A.
Dong, X.
Yu, Y.
Han, S.
Zeng, Z.
Zhang, R.
Lu, P.
Shi, H.
Tan, P.
Fan, S.
Shi, M.
Su, W.
ANNALS OF ONCOLOGY, 2023, 34 : S1656 - S1656
[9] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)-A multicenter single-arm phase II trial.
Rothschild, Sacha
Zippelius, Alfred
Eboulet, Eric, I
Savic, Spasenija
Betticher, Daniel C.
Bettini, Adrienne
Frueh, Martin
Joerger, Markus
Britschgi, Christian
Peters, Solange
Mark, Michael Thomas
Ochsenbein, Adrian
Janthur, Wolf Dieter
Waibel, Christine
Mach, Nicolas
Gonzalez, Michel
Froesch, Patrizia
Godar, Gilles
Rusterholz, Corinne
Pless, Miklos
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] PD-L1 Expression, EGFR and KRAS Mutations in First-Line Therapy (1L) for Non-Small Cell Lung Cancer (NSCLC) Patients
Cronin-Fenton, D.
Dalvi, T.
Hedgeman, E.
Norgaard, M.
Petersen, L.
Hansen, H.
Fryzek, J.
Lawrence, D.
Walker, J.
Mellemgaard, A.
Rasmussen, T.
Shire, N.
Rigas, J.
Potter, D.
Hamilton-Dutoit, S.
Sorensen, H.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2084 - S2085

← 1 2 3 4 5 →